does CBD help anxiety?

what the trials found

last verified: august 18, 2026. the five studies below are the whole basis for what this page claims. each citation was fetched live from PubMed and Europe PMC, and funding is recorded as what the funding statement actually said — or UNKNOWN, never inferred. numbered references link to the primary sources at the bottom of the page.

why the big meta-analysis and the famous trial disagree

they are answering different questions. the 2026 Lancet Psychiatry review asked whether cannabinoids treat mental disorders — pooling 54 randomised trials in 2,477 people, searched to May 2025 — and found no significant effect on anxiety, no randomised evidence at all for depression, and a rise in adverse events with a number needed to harm of 7 [1]. its conclusion was that routine use for mental disorders is currently rarely justified.

the studies that circulate as proof asked something narrower: does one large dose of pharmaceutical-grade CBD blunt anxiety during a stressful task in the next hour? in 24 never-treated patients with social anxiety disorder, a single 600 mg oral dose taken 90 minutes before a simulated public speaking test reduced anxiety, cognitive impairment and discomfort during the speech [2]. that is a real finding. it is also a one-dose laboratory challenge in 24 people, and it does not establish that daily CBD improves social anxiety in ordinary life.

a second gap sits underneath both: the human evidence has been acute-dosing evidence from the start. the most-cited review of CBD for anxiety concluded a decade ago that the animal work was strong while the human work was limited to single doses, with very few studies in people who actually had an anxiety disorder and essentially none on chronic dosing [4]. that assessment has not been overturned — it has simply gone unanswered.

is more CBD better?

no — and this is the most useful single fact on this page. when 57 healthy men were randomised to 150 mg, 300 mg, 600 mg or placebo before the same public speaking test, only the 300 mg dose significantly reduced anxiety. 150 mg and 600 mg were indistinguishable from placebo [3]. the curve is an inverted U, not a ladder.

that finding also has a commercial edge to it, and the disclosure is worth reading in full: the study drug was donated by STI-Pharm, four of the authors are co-inventors on a fluorinated-CBD patent, and the University of São Paulo has licensed that patent and holds an agreement with a pharmaceutical company to develop a synthetic CBD product for indications including anxiety disorders [3]. the funding is recorded as MIXED for exactly that reason — public grant money alongside donated drug and patent interests.

what does a retail CBD product actually contain?

often not what it says. laboratory analysis of 84 CBD products bought online found 26% contained less CBD than the label claimed and 43% contained more — roughly seven in ten mislabelled — with delta-9 THC detected in 21% of samples [5]. that study was funded by a cannabinoid research nonprofit on whose board three of the authors sit, and two authors disclose personal fees from cannabis companies; the result cuts against those commercial interests, which is why it is worth taking seriously rather than discounting.

stack that on top of the dose problem and the practical situation becomes clear. the doses with any evidence behind them are 300–600 mg of a pharmaceutical preparation. retail products deliver 10–50 mg, and you cannot be confident of even that number. no trial on this page tested what is in most people’s cupboards.

is CBD FDA-approved, and is it legal?

one CBD product is approved: Epidiolex, a purified plant-derived CBD oral solution, for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients aged 1 and older [6]. there is no FDA-approved psychiatric indication for CBD at all.

everything else is an unapproved consumer product operating in a gap. the 2018 Farm Bill removed hemp — cannabis containing no more than 0.3% delta-9 THC by dry weight — from the Controlled Substances Act, but FDA has stated it is unlawful to add CBD to food or to market it as a dietary supplement, denied three industry citizen petitions asking for a rulemaking to permit supplement marketing in january 2023, and concluded that the existing frameworks are not appropriate for CBD and that a new pathway from Congress would be needed [7]. in practice that means retail CBD is sold with no premarket review of potency, purity or claims — which is what the labelling study measured.

is CBD actually safe?

it is better tolerated than most things people worry about, and it is not inert. in the controlled epilepsy trials that supported Epidiolex, 12–13% of CBD-treated patients had ALT elevations above three times the upper limit of normal versus 1% on placebo, with some cases requiring hospitalisation; the risk rose with dose and with concomitant valproate [6]. CBD inhibits and induces multiple CYP and UGT enzymes, so it can raise or lower the blood levels of other drugs — the clobazam interaction is well documented, and the same mechanism applies to many psychiatric medications [6]. somnolence, sedation, diarrhoea and reduced appetite are common, and the approved labelling carries a warning for suicidal behaviour and ideation [6].

the meta-analysis puts a number on the general tolerability question: cannabinoids raised the odds of any adverse event (OR 1.75, 95% CI 1.25–2.46, number needed to harm 7) without raising serious adverse events [1]. so the realistic summary is not "dangerous" — it is "measurably more side effects, for no measured benefit on anxiety."

what would change this answer

an adequately powered randomised trial of chronic CBD dosing in people with a diagnosed anxiety disorder, at a dose someone can actually buy, run by investigators without a patent stake. none of the studies on this page is that trial, and the gap has been openly flagged in the literature for over a decade. if that trial appears, this page changes — that is what the "last verified" date at the top is for.

related evidence on resolv

CBD sits alongside sixteen other non-prescription substances in our supplements and non-prescription substances hub, which grades each one on regulatory status, evidence and risk — including cannabis and THC, where the strongest evidence is on the harm side. for the prescription side of the same question, see FDA-approved vs off-label.